Saturday 17 October 2026
Export ACON’s income statement to Excel — free account
Aclarion, Inc.
ACON Healthcare Health Information Services
Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024. In the quarter to June 2026, revenue grew 30.6%, EPS grew 59.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.85
0.10
−5.13%
Follow ACON
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
84.72 | 89.52 | 32.33 | 64.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.67) | (2.64) | (1.50) | (3.76) | |
P/B ratio |
0.42 | 0.35 | 0.19 | 0.35 | |
Price to Tangible BV |
0.45 | 0.38 | 0.21 | 0.39 | |
EV/Sales |
(107.19) | (151.91) | (123.47) | (100.17) | |
EV/EBITDA |
0.95 | 1.42 | 1.37 | 1.01 | |
EV/Operating CF |
1.11 | 1.62 | 1.30 | 1.05 | |
EV/FCF |
1.09 | 1.58 | 1.27 | 1.01 | |
Quick Ratio |
15.76 | 19.34 | 14.42 | 16.29 | |
Current Ratio |
16.20 | 19.65 | 14.81 | 17.01 | |
Net Debt/EBITDA |
5.75 | 6.50 | 6.23 | 6.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.00 | 0.01 | 0.01 | |
Operating CF/Net income |
0.97 | 0.93 | 0.86 | 0.68 | |
Capex/Depreciation |
(0.70) | (0.81) | (0.68) | (0.69) | |
Research and Development Expense of Revenue |
1,178.97% | 1,494.79% | 1,422.16% | 1,597.88% | |
Selling, General and Administrative Expense of Revenue |
10,360.71% | 12,679.15% | 9,360.54% | 8,112.70% | |
Intangible Assets out of Total Assets |
0.07 | 0.06 | 0.09 | 0.10 | |
Share Based Compensation of Revenue |
405.16% | 22.27% | 23.78% | 88.36% | |
Graham Net Nets |
2.22 | 2.64 | 4.72 | 2.57 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(256.94%) | (276.15%) | (369.78%) | (10,293.66%) | |
Free Cash Flow Yield |
(116.50%) | (107.33%) | (301.29%) | (152.99%) | |
Revenue per Share |
0.01 | 0.01 | 0.03 | 0.03 | |
Operating CF per Share |
(1.08) | (1.24) | (3.06) | (1.99) | |
Capex per Share |
(0.02) | (0.02) | (0.08) | (0.07) | |
Free Cash Flow per Share |
(1.10) | (1.26) | (3.14) | (2.06) | |
Cash per Share |
6.62 | 8.93 | 22.63 | 19.52 | |
Shareholders Equity per Share |
6.91 | 9.23 | 24.13 | 21.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.91 | 9.23 | 24.13 | 21.46 | |
Free Cash Flow |
(2.70) | (2.69) | (1.67) | (1.20) | |
Working Capital |
15.76 | 18.39 | 11.56 | 11.21 | |
Capital Expenditures |
(0.04) | (0.05) | (0.04) | (0.04) | |
Net Current Asset Value |
15.76 | 18.39 | 11.56 | 11.21 | |
EV/EBIT |
0.92 | 1.38 | 1.33 | 0.98 | |
Capex to Sales |
1.71 | 2.34 | 2.24 | 2.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.03 | 0.02 | 0.02 | |
Average Payables |
0.49 | 0.55 | 0.43 | 0.30 | |
Average Assets |
16.40 | 18.56 | 7.90 | 8.19 | |
Average Common Equity |
15.60 | 17.72 | 6.90 | 7.51 |
Columns are period end dates